Oral Jak Inhibitor Upadacitinib Use in Treatment of Pemphigus Foliaceus Case Report
Main Article Content
Keywords
autoimmune, blistering disease, pemphigus foliaceus, JAK inhibitor, upadacitinib
Abstract
Pemphigus foliaceus (PF) is a rare, blistering autoimmune condition that occurs when desmoglein-1 autoantibodies target and lead to loss of intercellular connections, resulting in blister formation on the skin. Current standard of care consists of highly immunosuppressive therapies such as prednisone, rituximab, and mycophenolate mofetil. A 43-year-old male with new-onset PF was treated with upadacitinib, a JAK inhibitor. He saw resolution of his blisters within 12 weeks of treatment and remains in remission from his PF. Our case demonstrates that JAK inhibition may prove to be an effective strategy in preventing dsg-1-triggered blisters. JAK1 inhibitors also may prove to be a safer, less immunosuppressive alternative to the highly immunosuppressive agents available today. Larger studies will be required to study the drug’s efficacy in others with PF.
References
2. Murrell, D. F., Peña, S., Joly, P., Marinovic, B., Hashimoto, T., Diaz, L. A., ... & Werth, V. P. (2020). Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 82(3), 575-585.
3. Hu, X., Li, J., Fu, M., Zhao, X., & Wang, W. (2021). The JAK/STAT signaling pathway: From bench to clinic. Signal transduction and targeted therapy, 6(1), 402.
4. Ferreira, S., Guttman-Yassky, E., & Torres, T. (2020). Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. American Journal of Clinical Dermatology, 21, 783-798.
5. Abramovits W, Cockerell C, Stevenson LC, Goldstein AM, Ehrig T, Menter A. PsEma--a hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed. 2005 Sep-Oct;4(5):275-81. doi: 10.1111/j.1540-9740.2005.03636.x. PMID: 16282748.
6. Pile, H. D., Yarrarapu, S. N. S., & Crane, J. S. (2021). Drug induced pemphigus. In StatPearls [Internet]. StatPearls Publishing.
7. Waschke, J., Bruggeman, P., Baumgartner, W., Zillikens, D., & Drenckhahn, D. (2005). Pemphigus foliaceus IgG causes dissociation of desmoglein 1–containing junctions without blocking desmoglein 1 transinteraction. The Journal of clinical investigation, 115(11), 3157-3165.
8. Tavakolpour, S., & Tavakolpour, V. (2016). Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine, 77, 189-195.
9. Walter, E., Vielmuth, F., Rotkopf, L., Sárdy, M., Horváth, O. N., Goebeler, M., ... & Waschke, J. (2017). Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus. Scientific reports, 7(1), 3579.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.